Skip to main content
. 2014 Apr 8;9(4):e94175. doi: 10.1371/journal.pone.0094175

Figure 6. AAV.iASPP inhibits p53 activation and downregulates retinal PUMA and Fas/CD95 levels.

Figure 6

Western blot analysis of axotomized retinal samples show that p53 phosphoserine15 (pSer15) levels are reduced in AAV.iASPP-treated retinas compared to control AAV.GFP at 24 hrs post-axotomy (A, C; ANOVA, * = p<0.05). Acetyl p53 levels remained unchanged (A, B; ANOVA, p>0.05). The p53 apoptotic targets PUMA and Fas/CD95 protein levels decrease in retinas treated with AAV.iASPP compared to AAV.GFP-treated control retinas (D, E, F; ANOVA, *** = p<0.005, ** = p<0.001), whereas Bax and Noxa remained unchanged (D, G, H; ANOVA, p>0.05).